Figure S1. CXCR4 antagonist AMD3100 inhibits R3A replication

a PBMCs were treated with the indicated drugs before infection with R3A, and viral infection efficiencies were measured by %p24+ cells with FACS analysis at 4 days post infection. Both AMD3100 (2μM and TAK-779 (5μM) were used at >IC90 dose as determined before in U373-CD4-CCR5/CXCR4 cells

b PBMCs were treated with AMD3100 before infection with R3A and maintained after infection. HIV-1 replication was measured by extracellular HIV-1 reverse transcriptase activity in the cell supernatant.

c CD4 T cell depletion by R3A in the presence of AMD3100 was measured by FACS analysis as described in Figure 1b. %CD4 T cells relative to mock infected PBMCs are presented.